16203796

Source:http://linkedlifedata.com/resource/pubmed/id/16203796

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0086418, umls-concept:C0243041, umls-concept:C0243044, umls-concept:C0439849, umls-concept:C1140680, umls-concept:C1520166, umls-concept:C1999216
pubmed:issue	19 Pt 1
pubmed:dateCreated	2005-10-5
pubmed:abstractText	To establish the pharmacokinetic and pharmacodynamic profile of the heat shock protein 90 (HSP90) inhibitor 17-allylamino, 17-demethoxygeldanamycin (17-AAG) in ovarian cancer xenograft models.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/17-(allylamino)-17-demethoxygeldanam..., http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzoquinones, http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers, http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase 4, http://linkedlifedata.com/resource/pubmed/chemical/HSP70 Heat-Shock Proteins, http://linkedlifedata.com/resource/pubmed/chemical/HSP90 Heat-Shock Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Lactams, Macrocyclic, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-raf, http://linkedlifedata.com/resource/pubmed/chemical/Rifabutin
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1078-0432
pubmed:author	pubmed-author:BanerjiUdaiU, pubmed-author:GrimshawRachelR, pubmed-author:JudsonIanI, pubmed-author:KellandLloydL, pubmed-author:RaynaudFlorenceF, pubmed-author:ValentiMelaniM, pubmed-author:WaltonMichaelM, pubmed-author:WorkmanPaulP
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	11
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	7023-32
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:16203796-Animals, pubmed-meshheading:16203796-Antineoplastic Agents, pubmed-meshheading:16203796-Benzoquinones, pubmed-meshheading:16203796-Biological Markers, pubmed-meshheading:16203796-Blotting, Western, pubmed-meshheading:16203796-Cell Line, Tumor, pubmed-meshheading:16203796-Cell Proliferation, pubmed-meshheading:16203796-Cyclin-Dependent Kinase 4, pubmed-meshheading:16203796-Dose-Response Relationship, Drug, pubmed-meshheading:16203796-Female, pubmed-meshheading:16203796-HSP70 Heat-Shock Proteins, pubmed-meshheading:16203796-HSP90 Heat-Shock Proteins, pubmed-meshheading:16203796-Humans, pubmed-meshheading:16203796-Inhibitory Concentration 50, pubmed-meshheading:16203796-Lactams, Macrocyclic, pubmed-meshheading:16203796-Lymphocytes, pubmed-meshheading:16203796-Mice, pubmed-meshheading:16203796-Neoplasm Transplantation, pubmed-meshheading:16203796-Ovarian Neoplasms, pubmed-meshheading:16203796-Proto-Oncogene Proteins c-raf, pubmed-meshheading:16203796-Rifabutin, pubmed-meshheading:16203796-Time Factors, pubmed-meshheading:16203796-Treatment Outcome
pubmed:year	2005
pubmed:articleTitle	Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
pubmed:affiliation	Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, United Kingdom.
pubmed:publicationType	Journal Article